Caplin Point Lab

{
  "main_header": {
    "sid": 640544,
    "name": "Caplin Point Lab",
    "stock_name": "Caplin Point Lab",
    "full_name": "Caplin Point Laboratories Ltd",
    "name_url": "stocks-analysis/caplin-point-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,820.00",
    "chg": -81.65,
    "chgp": "-4.29%",
    "dir": -1,
    "prev_price": "1,901.65",
    "mcapval": "14,025.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524742,
    "symbol": "CAPLIPOINT",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE475E01026",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "1.41 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/caplin-point-lab-640544-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Caplin Point Laboratories Gains 2.70%: Mixed Signals Amid Record Quarterly Results",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-gains-270-mixed-signals-amid-record-quarterly-results-3826471",
        "imagepath": "",
        "date": "2026-02-07 16:07:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock opens week at Rs.1,799.60, rising 1.23% despite Sensex decline</p>\n                    <p><strong>4 Feb:</strong> Technical momentum shift noted amid mixed market signals</p>\n                    <p><strong>5 Feb:</strong> Q3 FY26 results reveal strong profit growth but valuation concerns</p>\n                    <p><strong>6 Feb:</strong> Mixed quarterly performance reported amid margin pressure, stock dips 3.99%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,777.75</div></div>\n                    <div class=\"stat-item\"><div class..."
      },
      {
        "title": "Caplin Point Laboratories Ltd Reports Mixed Quarterly Performance Amid Margin Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-reports-mixed-quarterly-performance-amid-margin-pressure-3824597",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_fintrenddot_3824597.png",
        "date": "2026-02-06 16:00:18",
        "description": "Caplin Point Laboratories Ltd has reported its December 2025 quarter results, marking record highs in net sales and profitability metrics, yet facing challenges in operational efficiency and return ratios. The company’s financial trend has shifted from positive to flat, reflecting a nuanced performance that investors must carefully analyse amid a volatile pharmaceutical sector backdrop."
      },
      {
        "title": "Are Caplin Point Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-caplin-point-laboratories-ltd-latest-results-good-or-bad-3822915",
        "imagepath": "",
        "date": "2026-02-05 19:27:34",
        "description": "Caplin Point Laboratories Ltd reported its Q2 FY26 results, showcasing a consistent operational performance with notable metrics. The company achieved net sales of ₹534.04 crores, reflecting a year-on-year growth of 10.54%. This marks a continuation of double-digit revenue growth for seven consecutive quarters, indicating robust demand in its key markets, particularly in Latin America and Africa.\n\nThe net profit for the quarter stood at ₹154.45 crores, which represents an 18.08% increase compared to the previous year. This growth in profitability was supported by an operating margin of 35.42%, up 132 basis points from the same quarter last year, demonstrating effective cost management and operational efficiency.\n\nHowever, the company faced challenges in terms of market performance, as its stock has underperformed the broader market indices over the past year, leading to questions regarding the adequacy of c..."
      },
      {
        "title": "Caplin Point Laboratories Q3 FY26: Strong Profit Growth Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/caplin-point-laboratories-q3-fy26-strong-profit-growth-masks-valuation-concerns-3822652",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_quaterlyResult_3822652.png",
        "date": "2026-02-05 15:04:57",
        "description": "Caplin Point Laboratories Ltd., the Chennai-based pharmaceutical exporter, delivered a robust performance in Q2 FY26 (Jul-Sep'25), with consolidated net profit surging 18.08% year-on-year to ₹154.45 crores, marking its strongest quarterly earnings yet. However, the stock's premium valuation and bearish technical signals have prompted a cautious outlook, with shares trading at ₹1,902.70—down 20.62% from their 52-week high of ₹2,396.95."
      },
      {
        "title": "Caplin Point Laboratories Ltd Sees Technical Momentum Shift Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-sees-technical-momentum-shift-amid-mixed-market-signals-3819684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_technicaldot_3819684.png",
        "date": "2026-02-04 08:03:44",
        "description": "Caplin Point Laboratories Ltd has exhibited a notable shift in its technical momentum, with recent price action and indicator signals suggesting a transition from bearish to mildly bearish trends. Despite a strong intraday rally pushing the stock price to ₹1,904.40, technical indicators such as MACD, RSI, and moving averages present a nuanced picture, reflecting both resilience and caution for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Caplin Point Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-caplin-point-laboratories-ltd-fallingrising-3819346",
        "imagepath": "",
        "date": "2026-02-04 01:18:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Intraday Performance and Sector Support</strong></p>\n<p>The stock opened with a significant gap up of 4.89%, signalling strong buying interest from the outset of trading. It further touched an intraday high of ₹1,904.4, marking a 5.82% increase from the previous close. This outperformance was not isolated, as the Pharmaceuticals &amp; Drugs sector gained 2.77% on the same day, indicating a positive sentiment across the industry. Caplin Point outpaced its sector by 1.4%, underscoring its relative strength within the space.</p>\n<p>Despite the encouraging price action, the weighted average price suggests that more volume traded closer to the lower end of the day’s range, hinting at some profit-taking or cautious positioning by investors. Additionally, the stock’s price remains above its ..."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3812502",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/CaplinPointLabo_mojoScore_3812502.png",
        "date": "2026-01-31 10:10:33",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3795860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/CaplinPointLabo_mojoScore_3795860.png",
        "date": "2026-01-20 10:10:43",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3786721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/CaplinPointLabo_mojoScore_3786721.png",
        "date": "2026-01-09 10:10:44",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 583,
    "sid": "640544",
    "stock_news_url": "https://www.marketsmojo.com/news/caplin-point-laboratories-640544"
  },
  "announcements": [
    {
      "caption": "Financial Results For The Quarter Ended December 31 2025",
      "datetime": "05-Feb-2026",
      "details": "Unaudited standalone and Consolidated Financial Results for the Quarter and nine months ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
      "datetime": "05-Feb-2026",
      "details": "Outcome of the Board Meeting held on February 05 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "05-Feb-2026",
      "details": "Investor Presentation for the quarter and nine months ended December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Caplin Point Laboratories Ltd has declared <strong>150%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Caplin Point Laboratories Ltd has announced <strong>2:10</strong> stock split, ex-date: 19 Oct 16",
          "dt": "2016-10-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Caplin Point Laboratories Gains 2.70%: Mixed Signals Amid Record Quarterly Results

2026-02-07 16:07:14

Key Events This Week

2 Feb: Stock opens week at Rs.1,799.60, rising 1.23% despite Sensex decline

4 Feb: Technical momentum shift noted amid mixed market signals

5 Feb: Q3 FY26 results reveal strong profit growth but valuation concerns

6 Feb: Mixed quarterly performance reported amid margin pressure, stock dips 3.99%

Week Open

Rs.1,777.75

Read full news article

Caplin Point Laboratories Ltd Reports Mixed Quarterly Performance Amid Margin Pressure

2026-02-06 16:00:18

Caplin Point Laboratories Ltd has reported its December 2025 quarter results, marking record highs in net sales and profitability metrics, yet facing challenges in operational efficiency and return ratios. The company’s financial trend has shifted from positive to flat, reflecting a nuanced performance that investors must carefully analyse amid a volatile pharmaceutical sector backdrop.

Read full news article

Are Caplin Point Laboratories Ltd latest results good or bad?

2026-02-05 19:27:34

Caplin Point Laboratories Ltd reported its Q2 FY26 results, showcasing a consistent operational performance with notable metrics. The company achieved net sales of ₹534.04 crores, reflecting a year-on-year growth of 10.54%. This marks a continuation of double-digit revenue growth for seven consecutive quarters, indicating robust demand in its key markets, particularly in Latin America and Africa. The net profit for the quarter stood at ₹154.45 crores, which represents an 18.08% increase compared to the previous year. This growth in profitability was supported by an operating margin of 35.42%, up 132 basis points from the same quarter last year, demonstrating effective cost management and operational efficiency. However, the company faced challenges in terms of market performance, as its stock has underperformed the broader market indices over the past year, leading to questions regarding the adequacy of c...

Read full news article

Caplin Point Laboratories Q3 FY26: Strong Profit Growth Masks Valuation Concerns

2026-02-05 15:04:57

Caplin Point Laboratories Ltd., the Chennai-based pharmaceutical exporter, delivered a robust performance in Q2 FY26 (Jul-Sep'25), with consolidated net profit surging 18.08% year-on-year to ₹154.45 crores, marking its strongest quarterly earnings yet. However, the stock's premium valuation and bearish technical signals have prompted a cautious outlook, with shares trading at ₹1,902.70—down 20.62% from their 52-week high of ₹2,396.95.

Read full news article

Caplin Point Laboratories Ltd Sees Technical Momentum Shift Amid Mixed Market Signals

2026-02-04 08:03:44

Caplin Point Laboratories Ltd has exhibited a notable shift in its technical momentum, with recent price action and indicator signals suggesting a transition from bearish to mildly bearish trends. Despite a strong intraday rally pushing the stock price to ₹1,904.40, technical indicators such as MACD, RSI, and moving averages present a nuanced picture, reflecting both resilience and caution for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Why is Caplin Point Laboratories Ltd falling/rising?

2026-02-04 01:18:13

Strong Intraday Performance and Sector Support

The stock opened with a significant gap up of 4.89%, signalling strong buying interest from the outset of trading. It further touched an intraday high of ₹1,904.4, marking a 5.82% increase from the previous close. This outperformance was not isolated, as the Pharmaceuticals & Drugs sector gained 2.77% on the same day, indicating a positive sentiment across the industry. Caplin Point outpaced its sector by 1.4%, underscoring its relative strength within the space.

Despite the encouraging price action, the weighted average price suggests that more volume traded closer to the lower end of the day’s range, hinting at some profit-taking or cautious positioning by investors. Additionally, the stock’s price remains above its ...

Read full news article

Caplin Point Laboratories Ltd is Rated Sell

2026-01-31 10:10:33

Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Caplin Point Laboratories Ltd is Rated Sell

2026-01-20 10:10:43

Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Caplin Point Laboratories Ltd is Rated Sell

2026-01-09 10:10:44

Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News